Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Work In Process (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Work In Process for 2 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process rose 77.0% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a 77.0% increase, with the full-year FY2025 number at $4.3 million, up 77.0% from a year prior.
  • Work In Process was $4.3 million for Q4 2025 at Day One Biopharmaceuticals, down from $6.0 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.0 million in Q3 2025 to a low of $2.4 million in Q4 2024.